A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
To determine whether the combination of MM-111 plus paclitaxel and trastuzumab is more effective than paclitaxel and trastuzumab alone
Stanford is currently not accepting patients for this trial.
Intervention(s):
- drug: MM-111
- drug: Paclitaxel
- drug: Trastuzumab
Eligibility
Inclusion Criteria:
- Patients must have documentation of histologically or cytologically confirmed
metastatic or locally advanced adenocarcinoma of the distal esophagus, GE junction or
stomach
- Patients must have documentation of histologically or cytologically confirmed HER2
expression
- Patients must be ≥18 years of age
- Patients must have ECOG PS of 0, 1, or 2
- Patients must have adequate hematologic status, renal and hepatic function
Exclusion Criteria:
- Patients with known hypersensitivity to any of the components of MM-111
- Patients with a known history of hypersensitivity to paclitaxel or other drugs
formulated in Cremophor® EL
- Patients with a known history of hypersensitivity to trastuzumab or any of its
components (group 1 patients only)
- Patients with an active infection or with an unexplained fever >38.5°C
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting
Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation, mobile application development, and pharmaceutical trials.
Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.
